JAMA Dermatology Author Interviews
Jun 10, 2026 · 21 min · 8 segments
Interview with Joachim Hübner, MD, SJD, and Alexander Katalinic, MD, authors of Population Skin Cancer Screening and Melanoma Mortality Rates. Hosted by Adewole S. Adamson, MD, MPP. Related Content…
Joachim HübnerGuest
Alexander KatalinicGuest
Adewole S. AdamsonHostFrom the JAMA Network, this is JAMA Dermatology Author Interviews, conversations with authors exploring the latest clinical research, reviews, and opinions featured in JAMA Dermatology.
I'm Dr. Adai Adamson, the web editor for JAMA Dermatology and host of this podcast episode.
In most countries around the world, there are no universal standardized guidelines for skin cancer screening.
However, in Germany, since January 2008, men and women aged 35 and over who are covered by statutory or private health insurance are entitled to a visual whole body skin examination every two years.
Yet despite the scale of this national program, there's been limited evidence that it has reduced melanoma mortality in Germany.
In a new study published in JAMA Dermatology titled Population Skin Cancer Screening and Melanoma Mortality Rates, the authors examined melanoma mortality trends from 2009 through 2022 in Germany and compared them with trends in nine neighboring countries that do not have population-based skin cancer screening programs.
In this episode, we discuss what the authors found and what the results may mean for skin cancer screening research and policy.
With me on the podcast, I have Dr. Joachim Hubner, an epidemiologist who works at the Agency for Clinical Cancer Data of Lower Saxony in Oldenburg, Germany.
He's the first and corresponding author of this study and is here with his co-author, Dr. Alexander Katalinik, who is a general physician and professor of epidemiology at the University of Lübeck.
Read the full transcript.
Create an account to read the whole episode, search across every transcript, and follow the shows you care about.
From the JAMA Network, this is JAMA Dermatology Author Interviews, conversations with authors exploring the latest clinical research, reviews, and opinions featured in JAMA Dermatology.
I'm Dr. Adai Adamson, the web editor for JAMA Dermatology and host of this podcast episode.
In most countries around the world, there are no universal standardized guidelines for skin cancer screening.
However, in Germany, since January 2008, men and women aged 35 and over who are covered by statutory or private health insurance are entitled to a visual whole body skin examination every two years.
Yet despite the scale of this national program, there's been limited evidence that it has reduced melanoma mortality in Germany.
In a new study published in JAMA Dermatology titled Population Skin Cancer Screening and Melanoma Mortality Rates, the authors examined melanoma mortality trends from 2009 through 2022 in Germany and compared them with trends in nine neighboring countries that do not have population-based skin cancer screening programs.
In this episode, we discuss what the authors found and what the results may mean for skin cancer screening research and policy.
With me on the podcast, I have Dr. Joachim Hubner, an epidemiologist who works at the Agency for Clinical Cancer Data of Lower Saxony in Oldenburg, Germany.
He's the first and corresponding author of this study and is here with his co-author, Dr. Alexander Katalinik, who is a general physician and professor of epidemiology at the University of Lübeck.
